Main > RHEUMATOLOGY>OSTEOARTHRITIS > Treatment > InterLeukin-1 (IL-1) Inhibitors. > IL-1 Receptor AntAgonist (IL-1Ra) > Co.: DE. O (Autologous Ther/Patent) > Company s Web-Site Description
RTM. s serum is an autologous injection solution derived from the patient s blood. It may be used for the treatment of osteoarthritis and nerve root inflammation of different origin, such as disc prolapse. The basic idea for the development of this therapy was the fact that interleukin-1 (IL-1) plays a key role in the pathology of osteoarthritis or intervertebral disc degeneration/prolaps. The biological antagonist, interleukin-1 receptor antagonist (IL-1Ra), intervenes in the physiological mechanism of these diseases.
Interleukin-1-receptor antagonist (IL-1Ra) is naturally present in the blood. However, this antagonist is produced and extracted in higher concentrations with the production of RTM s prodt. To do this, blood is taken from the patient with a special syringe. During incubation at 37°C, the monocytes present in the blood are stimulated to produce IL-1Ra. This protein is then extracted, filled into ampoules and is subsequently available as an injectable substance for clinical use.
This cannot be compared to treatments using the patient s own blood that are often used in alternative medicine.
The RTM. s procedure is used throughout the world by more than 500 orthopaedic surgeons and rheumatologists. In Germany alone, more than 20,000 patients have been treated with RTM. s serum. Various clinical studies verify the high effectiveness and safety of this procedure.
Company s Web-Site Description's products
This section has no products